Enanta Pharmaceuticals to Present at Upcoming Investor Conference
May 14 2019 - 4:01PM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and
development-focused biotechnology company dedicated to creating
small molecule drugs for viral infections and liver diseases, today
announced that Jay R. Luly, Ph.D., President and Chief Executive
Officer, will participate in a fireside chat presentation format at
the following investor conference:
May 22, 1:35 p.m. ET; 2019 RBC Capital Markets Global Healthcare
Conference, New York City.
A live webcast of the presentation will be accessible by
visiting the “Events and Presentations” section on the “Investors”
page of Enanta’s website at www.enanta.com. A replay of the webcast
will be available following the presentation and will be archived
for approximately 30 days.
About EnantaEnanta Pharmaceuticals is using its robust,
chemistry-driven approach and drug discovery capabilities to become
a leader in the discovery and development of small molecule drugs
for the treatment of viral infections and liver diseases. Enanta’s
research and development efforts are currently focused on the
following disease targets: respiratory syncytial virus (RSV),
non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis
(PBC), and hepatitis B virus (HBV).
Enanta’s research and development activities are funded by
royalties from HCV products developed under its collaboration with
AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is
now sold by AbbVie in numerous countries as part of its newest
treatment for chronic hepatitis C virus (HCV) infection. This
leading HCV regimen is sold under the tradenames MAVYRET™ (U.S.)
and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir). Please visit
www.enanta.com for more information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190514005895/en/
Investor ContactCarol
Miceli617-607-0710cmiceli@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Sep 2023 to Sep 2024